We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Ahmed, S, Thomas, G, Ghoussaini, M, Healey, CS, Humphreys, MK, Platte, R, Morrison, J, Maranian, M, Pooley, KA, Luben, R, Eccles, D, Evans, DG, Fletcher, O, Johnson, N, Silva, ID, Peto, J, Stratton, MR, Rahman, N, Jacobs, K, Prentice, R, Anderson, GL, Rajkovic, A, Curb, JD, Ziegler, RG, Berg, CD, Buys, SS, McCarty, CA, Feigelson, HS, Calle, EE, Thun, MJ, Diver, WR, Bojesen, S, Nordestgaard, BG, Flyger, H, Dork, T, Schurmann, P, Hillemanns, P, Karstens, JH, Bogdanova, NV, Antonenkova, NN, Zalutsky, IV, Bermisheva, M, Fedorova, S, Khusnutdinova, E, Kang, D, Yoo, KY, Noh, DY, Ahn, SH, Devilee, P, van Asperen, CJ, Tollenaar, R, Seynaeve, C, Garcia-Closas, M, Lissowska, J, Brinton, L, Peplonska, B, Nevanlinna, H, Heikkinen, T, Aittomaki, K, Blomqvist, C, Hopper, JL, Southey, MC, Smith, L, Spurdle, AB, Schmidt, MK, Broeks, A, van Hien, RR, Cornelissen, S, Milne, RL, Ribas, G, Gonzalez-Neira, A, Benitez, J, Schmutzler, RK, Burwinkel, B, Bartram, CR, Meindl, A, Brauch, H, Justenhoven, C, Hamann, U, Chang-Claude, J, Hein, R, Wang-Gohrke, S, Lindblom, A, Margolin, S, Mannermaa, A, Kosma, VM, Kataja, V, Olson, JE, Wang, XS, Fredericksen, Z, Giles, GG, Severi, G, Baglietto, L, English, DR, Hankinson, SE, Cox, DG, Kraft, P, Vatten, LJ, Hveem, K, Kumle, M, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet2009; 41: 585–590.CrossRefGoogle ScholarPubMed
2
2.Caldas-Lopes, E, Cerchietti, L, Ahn, JH, Clement, CC, Robles, AI, Rodina, A, Moulick, K, Taldone, T, Gozman, A, Guo, Y, Wu, N, de Stanchina, E, White, J, Gross, SS, Ma, Y, Varticovski, L, Melnick, A, Chiosis, G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA2009; 106: 8365–8373.CrossRefGoogle ScholarPubMed
3
3.Cardamone, MD, Bardella, C, Gutierrez, A, Di Croce, L, Rosenfeld, MG, Di Renzo, MF, De Bortoli, M. ER alpha as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proc Natl Acad Sci U S A2009; 106: 7420–7425.CrossRefGoogle ScholarPubMed
4
4.Crowder, RJ, Phommaly, C, Tao, Y, Hoog, J, Luo, JQ, Perou, CM, Parker, JS, Miller, MA, Huntsman, DG, Lin, L, Snider, J, Davies, SR, Olson, JA, Watson, MA, Saporita, A, Weber, JD, Ellis, MJ. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res2009; 69: 3955–3962.CrossRefGoogle ScholarPubMed
5
5.Elsheikh, SE, Green, AR, Rakha, EA, Powe, DG, Ahmed, RA, Collins, HM, Soria, D, Garibaldi, JM, Paish, CE, Ammar, AA, Grainge, MJ, Ball, GR, Abdelghany, MK, Martinez-Pomares, L, Heery, DM, Ellis, IO. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res2009; 69: 3802–3809.CrossRefGoogle ScholarPubMed
6
6.Fan, P, Yue, W, Wang, JP, Aiyar, S, Li, Y, Kim, TH, Santen, RJ. Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models. Endocrinology2009; 150: 2036–2045.CrossRefGoogle ScholarPubMed
7
7.Feng, LY, Ou, ZL, Wu, FY, Shen, ZZ, Shao, ZM. Involvement of a novel chemokine decoy receptor CCX-CKR in breast cancer growth, metastasis and patient survival. Clin Cancer Res2009; 15: 2962–2970.CrossRefGoogle ScholarPubMed
8
8.Giamas, G, Castellano, L, Feng, Q, Knippschild, U, Jacob, J, Thomas, RS, Coombes, RC, Smith, CL, Jiao, LR, Stebbing, J. CK1 modulates the transcriptional activity of ER via AIB1 in an estrogen-dependent manner and regulates ERAIB1 interactions. Nucleic Acids Res2009; 37: 3110–3123.CrossRefGoogle Scholar
9
9.Haines, E, Minoo, P, Feng, Z, Resalatpanah, N, Nie, XM, Campiglio, M, Alvarez, L, Cocolakis, E, Ridha, M, Di Fulvio, M, Gomez-Cambronero, J, Lebrun, JJ, Ali, S. Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Mol Cell Biol2009; 29: 2505–2520.CrossRefGoogle ScholarPubMed
10
10.Heikkinen, T, Karkkainen, H, Aaltonen, K, Milne, RL, Heikkila, P, Aittomaki, K, Blomqvist, C, Nevanlinna, H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res2009; 15: 3214–3222.CrossRefGoogle ScholarPubMed
11
11.Hiscox, S, Jordan, NJ, Smith, C, James, M, Morgan, L, Taylor, KM, Green, TP, Nicholson, RI. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells. Breast Cancer Res Treat2009; 115: 57–67.CrossRefGoogle ScholarPubMed
12
12.Lagadec, C, Meignan, S, Adriaenssens, E, Foveau, B, Vanhecke, E, Romon, R, Toillon, RA, Oxombre, B, Hondermarck, H, Le Bourhis, X. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene2009; 28: 1960–1970.CrossRefGoogle ScholarPubMed
13
13.Lanigan, F, McKiernan, E, Brennan, DJ, Hegarty, S, Millikan, RC, McBryan, J, Jirstrom, K, Landberg, G, Martin, F, Duffy, MJ, Gallagher, WM. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer2009; 124: 2088–2097.CrossRefGoogle ScholarPubMed
14
14.Lott, ST, Chen, NY, Chandler, DS, Yang, QF, Wang, L, Rodriguez, M, Xie, HY, Balasenthil, S, Buchholz, TA, Sahin, AA, Chaung, K, Zhang, BL, Olufemi, SE, Chen, JY, Adams, H, Band, V, El-Naggar, AK, Frazier, ML, Keyomarsi, K, Hunt, KK, Sen, S, Haffty, B, Hewitt, SM, Krahe, R, Killary, AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer – art. no. e1000068. PLoS Med2009; 6: e1000068.CrossRefGoogle Scholar
15
15.Moraes, RC, Chang, H, Harrington, N, Landua, JD, Prigge, JT, Lane, TF, Wainwright, BJ, Hamel, PA, Lewis, MT. Ptch1 is required locally for mammary gland morphogenesis and systemically for ductal elongation. Development2009; 136: 1423–1432.CrossRefGoogle ScholarPubMed
16
16.Qin, L, Liu, ZL, Chen, HW, Xu, JM. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res2009; 69: 3819–3827.CrossRefGoogle ScholarPubMed
17
17.Rose-Hellekant, TA, Skildum, AJ, Zhdankin, O, Greene, AL, Regal, RR, Kundel, KD, Kundel, DW. Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors. Cancer Prev Res2009; 2: 496–502.CrossRefGoogle ScholarPubMed
19.Setiawan, VW, Monroe, KR, Wilkens, LR, Kolonel, LN, Pike, MC, Henderson, BE. Breast cancer risk factors defined by estrogen and progesterone receptor status. Am J Epidemiol2009; 169: 1251–1259.CrossRefGoogle ScholarPubMed
20
20.Sikora, MJ, Cordero, KE, Larios, JM, Johnson, MD, Lippman, ME, Rae, JM. The androgen metabolite 5 alpha-androstane-3 beta,17 beta-diol (3 beta Adiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat2009; 115: 289–296.CrossRefGoogle Scholar
21
21.Soni, S, Lin, BT, August, A, Nicholson, RI, Kirsch, KH. Expression of a phosphorylated p130(Cas) substrate domain attenuates the phosphatidylinositol 3-kinase/akt survival pathway in tamoxifen resistant breast cancer cells. J Cell Biochem2009; 107: 364–375.CrossRefGoogle ScholarPubMed
22
22.Thomas, G, Jacobs, KB, Kraft, P, Yeager, M, Wacholder, S, Cox, DG, Hankinson, SE, Hutchinson, A, Wang, Z, Yu, K, Chatterjee, N, Garcia-Closas, M, Gonzalez-Bosquet, J, Prokunina-Olsson, L, Orr, N, Willett, WC, Colditz, GA, Ziegler, RG, Berg, CD, Buys, SS, McCarty, CA, Feigelson, HS, Calle, EE, Thun, MJ, Diver, R, Prentice, R, Jackson, R, Kooperberg, C, Chlebowski, R, Lissowska, J, Peplonska, B, Brinton, LA, Sigurdson, A, Doody, M, Bhatti, P, Alexander, BH, Buring, J, Lee, IM, Vatten, LJ, Hveem, K, Kumle, M, Hayes, RB, Tucker, M, Gerhard, DS, Fraumeni, JF, Hoover, RN, Chanock, SJ, Hunter, DJ. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet2009; 41: 579–584.CrossRefGoogle ScholarPubMed
23
23.Udler, MS, Meyer, KB, Pooley, KA, Karlins, E, Struewing, JP, Zhang, J, Doody, DR, MacArthur, S, Tyrer, J, Pharoah, PD, Luben, R, Bernstein, L, Kolonel, LN, Henderson, BE, Le Marchand, L, Ursin, G, Press, MF, Brennan, P, Sangrajrang, S, Gaborieau, V, Odefrey, F, Shen, CY, Wu, PE, Wang, HC, Kang, D, Yoo, KY, Noh, DY, Ahn, SH, Ponder, BAJ, Haiman, CA, Malone, KE, Dunning, AM, Ostrander, EA, Easton, DF. FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet2009; 18: 1692–1703.CrossRefGoogle ScholarPubMed
24
24.Zhang, Y, Martens, JWM, Yu, JX, Jiang, J, Sieuwerts, AM, Smid, M, Klijn, JGM, Wang, YX, Foekens, JA. Copy number alterations that predict metastatic capability of human breast cancer. Cancer Res2009; 69: 3795–3801.CrossRefGoogle ScholarPubMed